Rapid Growth in Germany Glioblastoma Multiforme Therapeutics Market Forecasts to 2019

1
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 - CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth
Price Single User US3500
Corporate User US10500
2
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 - CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth
A leading business intelligence provider, has
released its latest research report "Cystic
Fibrosis Therapeutics in Major Developed Markets
to 2019 CFTR Modulators Initiate Drive towards
Personalized Treatment and Market Growth". The
value of the Cystic Fibrosis (CF) market is
expected to increase significantly in value over
the forecast period across the leading eight
developed nations, from 695.6 million in 2012 to
almost 4.5 billion in 2019. This equates to a
Compound Annual Growth Rate (CAGR) of 30.4.
Novel treatments with disease-modifying
mechanisms of action are the primary factor
driving the growth of the value of the market.
The positive impact of new market entrants will
offset the effects of key patent losses during
the forecast period. Cystic Fibrosis
Transmembrane conductance Regulators (CFTR)
modulators are the first type of CF therapy to
treat the root cause of the disease rather than
the symptoms, and as a result, they offer
patients improved relief and quality of life.
Kalydeco (ivacaftor), which has been marketed
since 2012, was the first CFTR modulator to reach
the market, and despite only treating a small
proportion of the CF population, it had a large
impact on the value of the market. This effect
will be repeated on a larger scale when
lumacaftor and Ataluren (PTC124) enter the
market, as these treatments can be used for a
much larger proportion of the CF population.
Vertex Pharmaceuticals Inc. are the developers of
Kalydeco, lumacaftor and other early phase CFTR
modulators, and are therefore expected to play a
key role in the development of the future CF
market.
Complete report available _at_ http//www.reportsnrep
orts.com/reports/274854-cystic-fibrosis-therapeuti
cs-in-major-developed-markets-to-2019-cftr-modulat
ors-initiate-drive-towards-personalized-treatment-
and-market-growth.html .
3
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 - CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth

• The pricing of CFTR modulators will be premium
  due to the clinical benefits and
  disease-modifying effects that they represent.
  Symptomatic therapies will be used in conjunction
  with CFTR modulators, and will still be a
  necessary part of the CF treatment plan. The
  antibiotics segment in particular is expected to
  become overcrowded and competitive over the
  forecast period, due to cheap, generic tobramycin
  products and novel market entrants competing for
  market share.
• Scope
• The report assesses the current CF market, and
  predicts market trends to 2019, analyzing key
  drivers and barriers. The areas covered include
• A disease introduction, which defines the
  disease, including symptoms, diagnosis and
  treatment.
• An analysis of the CF marketed landscape,
  including a comparison of the efficacy and safety
  of the most prominent brands, as well as the
  unmet needs of CF treatment.
• A detailed analysis of the CF pipeline,
  detailing, among other parameters, drug
  distribution by phase, molecule type and
  mechanism of action. The CF clinical trial
  landscape is then analyzed, with a particular
  emphasis on failure rates across different trial
  phases as well as the trends in clinical trial
  size and duration. This section also includes
  profiles and single product forecasts for the
  most promising pipeline drugs.
• An epidemiological forecast of the major CF
  markets. The projected values include total and
  treated populations.
• An in-depth forecasting model for the CF market,
  which considers the current marketed therapies,
  in addition to the potential entry of new
  products into the market. The model consists of a
  projected outcome, with high and low variance
  results, depending on the potential performance
  of pipeline therapies.

Buy a copy of this report _at_ http//www.reportsnrep
orts.com/purchase.aspx?name274854 .
4
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 - CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth
Table of Contents 1 Table of Contents 41.1 List
of Tables 51.2 List of Figures 6 2 Introduction
72.1 Disease Introduction 72.2 Symptoms 82.3
Etiology 82.4 Pathophysiology 92.5 Diagnosis
92.6 Prognosis 102.7 Assessment of Disease
Severity 102.8 Treatment 10 3 Marketed Products
123.1 Overview 123.2 Product Profiles 133.2.1
Pulmozyme (dornase alfa) - Genentech 133.2.2
Bronchitol (mannitol) - Pharmaxis 143.2.3 TOBI
(tobramycin) - Novartis 153.2.4 TOBI Podhaler
(tobramycin) - Novartis 163.2.5 Bramitob/Bethkis
(tobramycin) - Chiesi Farmaceutici 17
Browse more research reports on Pharmaceuticals
Market _at_ http//www.reportsnreports.com/market-re
search/pharmaceuticals/ .
5
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 - CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth
3 Marketed Products 12 3.2.6 Colobreathe
(colistimethate sodium) - Forest Laboratories
173.2.7 Cayston (aztreonam) - Gilead Sciences
183.2.8 Kalydeco (ivacaftor) - Vertex
Pharmaceuticals 193.2.9 Pancreatic Enzyme
Replacement Therapies 203.2.10 Other Successful
Products 213.3 Heat Map of Marketed Products
213.4 Conclusion 23 4 Developmental Pipeline
25 4.1 Overview 254.2 Mechanisms of Action in
the Pipeline 274.3 Clinical Trials 304.3.1
Failure Rate 304.3.2 Clinical Trial Duration
314.3.3 Clinical Trial Size 324.4 Promising
Pipeline Molecules 35 4.4.1 Lumacaftor (VX809) -
Vertex Pharmaceuticals 354.4.2 Ataluren (PTC124)
- PTC Therapeutics 374.4.3 Aeroquin
(levofloxacin) - Aptalis Pharma 384.4.4 Arikace
(amikacin liposomal) - Insmed 404.4.5 Other
Promising Molecules 41
Browse more research reports on Pharmaceuticals
Market _at_ http//www.reportsnreports.com/market-re
search/pharmaceuticals/ .
6
Cystic Fibrosis Therapeutics in Major Developed
Markets to 2019 - CFTR Modulators Initiate Drive
towards Personalized Treatment and Market Growth

• Reasons to buy
• The report enables clients to develop a strong
  understanding of CF as a disease and a market.
  The current therapeutic needs and future market
  trends contained in this report will highlight
  market opportunities and the scope of competition
  between CF therapeutics. Primarily, the report
  will allow clients to
• Understand the CF pipeline and the clinical
  needs it is addressing. In particular, the
  importance and benefits of Cystic Fibrosis
  Therapeutics Market modulators are highlighted
  and compared with symptomatic treatments.
• Develop their knowledge of key products that may
  enter the market before 2019. Detailed profiles
  of these products are provided, with a focus on
  their clinical trial performance, as well as how
  they can be incorporated into the CF treatment
  plan and what competition they face.
• Assess the risk associated with CF clinical
  trials compared with both industry and therapy
  area averages. In addition, in order to
  understand the trends in both trial size and
  duration according to mechanism of action or
  molecule type.
• Identify patterns of growth in the CF market
  over the forecast period and understand the
  underlying causes, as well as observing the
  contributions made by each major market to this
  growth.
• Inquire discount on this report _at_
  http//www.reportsnreports.com/contacts/discount.a
  spx?name274854 .

Browse more research reports on Pharmaceuticals
Market _at_ http//www.reportsnreports.com/market-re
search/pharmaceuticals/ .
7
About ReportsnReports
ReportsnReports.com is your single source for all
market research needs. Our database includes
250,000 syndicated market research reports from
100 leading global publishers covering in-depth
analysis of over 5000 micro markets. With
comprehensive information about the publishers
and their report methodology, data sources, etc.
we help you in your purchase decision by mapping
your information needs with the most relevant
available reports in our library. Connect with
us sales_at_reportsandreports.com 1 888 391 5441
Contact sales_at_reportsandreports.com for further
information.
Contact sales_at_reportsandreports.com for further
information.